Popular Articles

Israeli Startup CLT Partners With Dutch Erasmus Medical Centre To Develop A Cure For Atrial Fibrillation
Today, the Israeli medtech startup company CLT Ltd. announced the establishment of Closed Loop Therapies (CLT) BV - a joint venture between Erasmus University Medical Centre (Rotterdam, the Netherlands), a highly prominent medical institute in Europe, and CLT Israel. The joint venture aims to develop and commercialise a novel therapeutic system, consisting of an arrhythmia-detecting drug pump combined with a unique drug, for automatic and immediate treatment of emerging atrial fibrillation (AF). Market size is estimated at 2.5-3 billion Euro, annually.
generic viagra online
'Complacency,' 'Stigma' Hindering Efforts To Reduce HIV/AIDS In Black Communities, Opinion Piece Says
"Nearly 30 years after the discovery of HIV and AIDS, the epidemic is still ravaging black neighborhoods in Baltimore and across the nation," Kevin Fenton -- director of CDC"s National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention -- writes in a Baltimore Sun opinion piece. Fenton writes that "complacency about HIV and the continued stigma associated with the disease are hindering progress by preventing too many African-Americans from seeking either HIV testing and treatment or support from their friends and family," adding that "this is a challenge that can be overcome."According to Fenton, the Obama administration last month "took an important step in confronting the United States" HIV epidemic" when CDC and White House officials announced a five-year campaign called Act Against AIDS, which is "designed to refocus the nation"s attention on the HIV crisis here at home." Fenton notes that 14 black civic organizations -- including the NAACP, the National Urban League, the Southern Christian Leadership Conference and the National Council of Negro Women -- are "joining the CDC to increase knowledge, awareness and action within black communities across the country." He adds that the campaign "will harness the strength and reach of these organizations by enhancing their ability to make HIV prevention a core component of their daily activities." "By raising the visibility of HIV and AIDS, the new campaign also aims to confront and overcome the fear and stigma that help keep HIV alive in black communities," Fenton says. He adds that he has "been encouraged in recent years to see black leaders, including black faith leaders, speak out more openly across the nation about the need to confront HIV and the stigma that persists surrounding this disease." Fenton writes that "[e]nding this epidemic will require not only frank and difficult discussions about HIV but also a shared sense of responsibility and commitment," concluding, "All of us can and must be part of the solution" (Fenton, Baltimore Sun, 5/27).
News of the day
St. Jude Medical Announces FDA Approval Of The Cool Point Irrigation Pump
St. Jude Medical, Inc. (NYSE:STJ) announced U.S. Food and Drug Administration (FDA) approval of its Cool Point™ Irrigation Pump. Used in conjunction with SJM open-irrigated ablation catheters, an irrigation pump supplies a continuous flow of saline through the catheter"s inner lumen to cool the ablation electrode for more effective energy delivery. Designed to enhance physicians" ability to perform successful atrial ablations, the new Cool Point irrigation pump was developed specifically for use with the company"s IBI-1500T9-CP cardiac ablation generator and family of Therapy™ Cool Path™ irrigated catheters.
Nutrition

New Mechanism Fundamental To The Spread Of Invasive Yeast Infections Identified

A group of researchers led by Carnegie Mellon University Biological Sciences Professor Aaron Mitchell has identified a novel regulatory gene network that plays an important role in the spread of common, and sometimes deadly, yeast infections. The findings, which establish the role of Zap1 protein in the activation of genes that regulate the synthesis of biofilm matrix, will be published in the June 16, 2009, issue of PLoS Biology, a peer-reviewed open-access journal from the Public Library of Science. Candida albicans is a fungus, more specifically a yeast, which approximately 80 percent of people have in their gastrointestinal and genitourinary tract with no ill effects. However, at elevated levels it can cause non-life threatening conditions like thrush and yeast infections. A C. albicans infection becomes much more serious, and can be lethal, in those with compromised immune systems who have an implantable medical device, such as a pacemaker or artificial joint, or who use broad-spectrum antibiotics. Approximately 60,000 Americans develop such invasive C. albicans infections each year. Central to such infections is a substance called biofilm matrix. A biofilm is a population of microbes, in this case C. albicans cells, joined together to form a sheet of cells. The cells in the biofilm produce extracellular components such as proteins and sugars, which form a cement-like substance called matrix. This matrix serves to protect the cells of the biofilm, preventing drugs and other stressors from attacking the cells while acting as a glue that holds the cells together. By doing this, the matrix provides an environment in which yeast cells in the biofilm can thrive, promoting infection and drug resistance. "Biofilms have a major impact on human health and matrix is such a pivotal component of biofilms. It is important to understand how the production of matrix is regulated," Mitchell said. In the study published in PLoS, Mitchell and colleagues found that the zinc-responsive regulatory protein Zap1 prevents the production of soluble í²-1,3 glucan, a sugar that is a major component of matrix. They also identified other genes whose expression is controlled by Zap1, called Zap1 target genes. They found that these genes encode for two types of enzymes, glucoamylases and alcohol dehydrogenases, which both govern the production and maturation of matrix components. "Understanding this novel regulatory gene network gives us insight into the metabolic processes that contribute to biofilm formation, and the role the network plays in infection," Mitchell said. "By better understanding the mechanisms by which biofilms develop and grow, we can start to look at targets for combating infection." According to Mitchell, the next steps will be to determine the mechanisms by which Zap1 target genes regulate matrix production. Understanding and targeting these mechanisms will allow the researchers to develop therapeutic small molecules that will block biofilm formation and diagnostic tools that can detect biofilms before infections spread. This study was funded by the National Institutes of Health. Other study authors include: Clarissa J. Nobile, Aaron Hernday, Oliver R. Homann, and Alexander D. Johnson, Department of Microbiology and Immunology, University of California, San Francisco; Jeniel E. Nett and David R. Andes, Department of Medicine, University of Wisconsin; and Jean-Sebastien Deneault, and Andre Nantel, Biotechnology Research Institute, National Research Council of Canada. Jocelyn Duffy Carnegie Mellon University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):